1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Cures Within Reach – Clinical Trials to Validate AI-Driven Drug Repurposing is sponsored by Cures Within Reach. This grant supports investigator-initiated, proof-of-concept, Phase I or Phase IIA clinical trials to validate artificial intelligence (AI)-driven repurposing opportunities in any unsolved disease.
The therapies supported by AI models must already be approved, and eligible trials must include AI-generated data as part of the preclinical support for the trial. This could be highly relevant for identifying existing drugs that AI suggests could be effective in colorectal cancer.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Investigator-initiated projects, likely targeting academic institutions and research organizations. Requires an institutional match. Confirm the full requirements in the official notice before applying.
The current listing shows up to $100,000 (plus 10% institutional match). Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was June 26, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Cures Within Reach – Clinical Trials to Validate AI-Driven Drug Repurposing is funded by Cures Within Reach. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Clinical Repurposing for Veterans Initiative is sponsored by Cures Within Reach. This initiative focuses on finding and funding clinical repurposing trials that address unmet and high-priority medical needs of veterans and active military, including brain injuries. This is a very strong fit for a nonprofit focused on neurological conditions and veterans.
Funding Opportunities / RFPs (Cures Within Reach) is sponsored by Cures Within Reach. Cures Within Reach's mission is to improve patient quality and length of life by leveraging the speed, safety and cost-effectiveness of testing already approved therapies for new indications that serve philanthropic and/or commercial uses, driving more treatments to more patient…
AI Validation - Clinical Trials to Validate AI-Driven Drug Repurposing is sponsored by Cures Within Reach. This program supports investigator-initiated, proof-of-concept, Phase I or Phase IIA clinical trials to validate AI-driven repurposing opportunities for approved therapies in any unsolved disease. Eligible trials must include AI-generated data as part of the preclinical support.
On July 30, 2026, five food and farming nonprofits sued USDA in the Western District of Washington over grant terms and conditions that restrict what grantees may say and do — including with money that never came from the federal government. Twenty states and DC filed a parallel challenge in March. Here is what the conditions actually say and what recipients should do before their next award letter arrives.
Read articleHRSA-26-078 splits $9.1 million among roughly 10 Public Health Training Centers, with awards up to $910,000 and applications due July 17, 2026. Eligibility runs to accredited schools of public health and other nonprofit training institutions. Here's why the winning applications are the ones that can prove an existing, mapped relationship with state and local health departments — not the ones promising the slickest coursework.
Read articleThe Department of Education's May 19 final rule activates Workforce Pell on July 1, 2026, opening federal aid to short-term training programs as brief as 8 weeks. Governors and state workforce boards — not accreditors — pick the eligible industries, and only programs that pass earnings-vs-cost gates make the list.
Read article